Chien Li
Associate Director Novo Nordisk
Seminars
Wednesday 15th July 2026
Advancing Multi-Modal Incretin Synergies & Oral Maintenance Continuums to Match Bariatric Outcomes & Preserve Functional Vitality
9:00 am
- Advancing the CagriSema portfolio (Semaglutide + Cagrilintide) to match bariatric outcomes, utilizing dual-pathway synergy between incretin and amylin receptors to drive deeper body weight reduction while specifically preserving physical vitality and metabolic rate
- Benchmarking REDEFINE clinical data against current “gold standard” dual-agonists to prove superior 68-week weight stability, providing the robust longitudinal data required for universal global payer support and expanded cardiovascular indication labeling
- Standardizing lean-mass-to-fat-mass ratios as a core regulatory endpoint in multi-targeted trials, ensuring that “maximum weight loss” translates into high-quality metabolic health and functional physical independence for aging populations
